Sage Journals: Discover world-class research

Abstract

State policies requiring clinicians to review prescription drug monitoring program (PDMP) databases have proliferated. However, patient advocates suggest these policies may adversely affect patients with chronic pain. This study aimed to quantify the effect of must-access PDMP implementation on pain and physical impairment. Using panel data on 34,431 older adults from the Health and Retirement Study (2002–2021), we conducted a heterogeneity-robust difference-in-differences analysis. Must-access PDMPs were associated with a 1.65 (95% CI: 0.43 to 2.87) percentage point increase in frequent pain during the two-year window surrounding policy implementation and a peak 3.52 (95% CI: 0.88 to 6.16) percentage point increase in the second post-policy period, after which the effect dissipated. Effects on impairment outcomes were positive but statistically insignificant. Findings suggest that must-access PDMP policies may increase numbers of older adults reporting frequent pain in the early policy implementation years, though they were not associated with statistically detectable changes in physical impairment.

Keywords

older adults opioids pain prescription drug monitoring programs

Get full access to this article

View all access options for this article.

References

Agree

E. M.

Wolf

D. A.

(2017). Disability measurement in the health and retirement study. Forum Health Econ Policy, 21(1), Article e0029. https://doi.org/10.1515/fhep-2017-0029

Anson

(2017). Survey finds CDC opioid guidelines harming patients. https://www.painnewsnetwork.org/stories/2017/3/13/survey-finds-cdc-opioid-guidelines-harming-patients

Antoniou

Ala-Leppilampi

Shearer

Parsons

J. A.

Tadrous

Gomes

(2019). “Like being put on an ice floe and shoved away”: A qualitative study of the impacts of opioid-related policy changes on people who take opioids. International Journal of Drug Policy, 66, 15–22. https://doi.org/10.1016/j.drugpo.2019.01.015

Bao

Zhang

Wen

Johnson

Jeng

P. J.

Witkin

L. R.

Nicholson

Reid

M. C.

Schackman

B. R.

(2021). Robust prescription monitoring programs and abrupt discontinuation of long-term opioid use. American Journal of Preventive Medicine, 61, 537–544. https://doi.org/10.1016/j.amepre.2021.04.019

Benjamin

E. J.

Virani

S. S.

Callaway

C. W.

Chamberlain

A. M.

Chang

A. R.

Cheng

Chiuve

S. E.

Cushman

Delling

F. N.

Deo

de Ferranti

S. D.

Ferguson

J. F.

Fornage

Gillespie

Isasi

C. R.

Jiménez

M. C.

Jordan

L. C.

Judd

S. E.

Lackland

. . .Muntner

(2018). Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation, 137(12), e67–e492. https://doi.org/10.1161/cir.0000000000000558

Buchmueller

T. C.

Carey

(2018). The effect of prescription drug monitoring programs on opioid utilization in Medicare. American Economic Journal: Economic Policy, 10(1), 77–112. https://doi.org/10.1257/pol.20160094

Callaway

Sant’Anna

P. H. C.

(2021). Difference-in-Differences with multiple time periods. Journal of Econometrics, 225(2), 200–230. https://doi.org/10.1016/j.jeconom.2020.12.001

Coleman

Lennon

R. P.

Garza

R. H.

Veasley

Kuchera

Edwards

Zgierska

A. E.

(2023). Shifting quality chronic pain treatment measures from processes to outcomes. Journal of Opioid Management, 19(7), 83–94. https://doi.org/10.5055/jom.2023.0802

Colloca

(2019). The placebo effect in pain therapies. Annual Review of Pharmacology and Toxicology, 59, 191–211. https://doi.org/10.1146/annurev-pharmtox-010818-021542

10.

Covinsky

K. E.

Lindquist

Dunlop

D. D.

Yelin

(2009). Pain, functional limitations, and aging. Journal of the American Geriatrics Society, 57(9), 1556–1561. https://doi.org/10.1111/j.1532-5415.2009.02388.x

11.

Dahlhamer

Lucas

Zelaya

Nahin

Mackey

DeBar

Kerns

Von Korff

Porter

Helmick

(2018). Prevalence of chronic pain and high-impact chronic pain among adults: United States, 2016. https://www.cdc.gov/mmwr/volumes/67/wr/mm6736a2

12.

Darnall

B. D.

Juurlink

Kerns

R. D.

Mackey

Van Dorsten

Humphreys

Gonzalez-Sotomayor

J. A.

Furlan

Gordon

A. J.

Gordon

D. B.

Hoffman

D. E.

Katz

Kertesz

S. G.

Satel

Lawhern

R. A.

Nicholson

K. M.

Polomano

R. C.

Williamson

O. D.

McAnally

. . .Lovejoy

(2019). International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Medicine, 20(3), 429–433. https://doi.org/10.1093/pm/pny228

13.

Davis

C. S.

Lieberman

A. J.

Hernandez-Delgado

Suba

(2019). Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: A national systematic legal review. Drug and Alcohol Dependence, 194, 166–172. https://doi.org/10.1016/j.drugalcdep.2018.09.022

14.

Davis

C. S.

Piper

B. J.

Gertner

A. K.

Rotter

J. S.

(2020). Opioid prescribing laws are not associated with short-term declines in prescription opioid distribution. Pain Medicine, 21(3), 532–537. https://doi.org/10.1093/pm/pnz159

15.

Dobscha

S. K.

Corson

Flores

J. A.

Tansill

E. C.

Gerrity

M. S.

(2008). Veterans affairs primary care clinicians’ attitudes toward chronic pain and correlates of opioid prescribing rates. Pain Medicine, 9(5), 564–571. https://doi.org/10.1111/j.1526-4637.2007.00330.x

16.

Dowell

Haegerich

T. M.

Chou

(2016). CDC guideline for prescribing opioids for chronic pain: United States, 2016. Journal of the American Medical Association, 315(15), 1624–1645. https://doi.org/10.1001/jama.2016.1464

17.

Dowell

Ragan

Jones

Baldwin

Chou

(2022). CDC clinical practice guideline for prescribing opioids for pain: United States, 2022. https://doi.org/10.15585/mmwr.rr7103a1

18.

Dowell

Zhang

Noonan

R. K.

Hockenberry

J. M.

(2016). Mandatory provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Affairs, 35(10), 1876–1883. https://doi.org/10.1377/hlthaff.2016.0448

19.

Fenton

J. J.

Agnoli

A. L.

Xing

Hang

Altan

A. E.

Tancredi

D. J.

Jerant

Magnan

(2019). Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008–2017. Journal of the American Medical Association Network Open, 2(11), Article e1916271. https://doi.org/10.1001/jamanetworkopen.2019.16271

20.

Finley

E. P.

Garcia

Rosen

McGeary

Pugh

M. J.

Potter

J. S.

(2017). Evaluating the impact of prescription drug monitoring program implementation: A scoping review. BMC Health Services Research, 17, Article 420. https://doi.org/10.1186/s12913-017-2354-5

21.

Florence

Luo

Rice

(2021). The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend, 218, Article 108350. https://doi.org/10.1016/j.drugalcdep.2020.108350

22.

Fornili

(2018). The opioid crisis, suicides, and related conditions: Multiple clustered syndemics, not singular epidemics. Journal of Addictions Nursing, 29(3), 214–220. https://doi.org/10.1097/jan.0000000000000240

23.

Gaskin

D. J.

Richard

(2012). The economic costs of pain in the United States. The Journal of Pain, 13(8), 715–724. https://doi.org/10.1016/j.jpain.2012.03.009

24.

Georgia Composite Medical Board. (2018). Rule 360-38-04: Requirements for checking the PDMP. https://rules.sos.ga.gov/GAC/360-38-.04

25.

Gleason

R. M.

Kirsh

K. L.

Passik

S. D.

Chambers

J. F.

(2014). Current access to opioids: Survey of chronic pain patients. Practical Pain Management, 18, 100580.

26.

Goodin

A. J.

(2018). We cannot treat the dead. American Journal of Public Health, 108(10), 1286–1288. https://doi.org/10.2105/ajph.2018.304658

27.

Gross

Gordon

D. B.

(2019). The strengths and weaknesses of current U.S. policy to address pain. American Journal of Public Health, 109(1), 66–72. https://doi.org/10.2105/ajph.2018.304746

28.

Health and Retirement Study. (2017). Aging in the 21st century: Challenges and opportunities for Americans. https://hrsonline.isr.umich.edu/sitedocs/databook/inc/pdf/HRS-Aging-in-the-21St-Century.pdf

29.

Health and Retirement Study. (2025). Produced and distributed by the University of Michigan with funding from the National Institute on Aging (Grant number NIA U01AG009740).

30.

Heeringa

Connor

(1995). Technical description of the health and retirement survey sample design. https://hrs.isr.umich.edu/publications/biblio/5310

31.

Holmgren

A. J.

Botelho

Brandt

A. M.

(2020). A history of prescription drug monitoring programs in the United States: Political appeal and public health efficacy. American Journal of Public Health, 110(8), 1191–1197. https://doi.org/10.2105/ajph.2020.305696

32.

Hoppe

Karimi

Khalil

(2022). Mapping the research addressing prescription drug monitoring programs: A scoping review. Drug and Alcohol Review, 41(4), 803–817. https://doi.org/10.1111/dar.13431

33.

Horwitz

J. R.

Davis

McClelland

Fordon

Meara

(2021). The importance of data source in prescription drug monitoring program research. Health Services Research, 56(2), 268–274. https://doi.org/10.1111/1475-6773.13548

34.

Human Rights Watch. (2018). Not allowed to be compassionate: Chronic pain, the overdose crisis, and unintended harms in the U.S. https://www.hrw.org/report/2018/12/18/not-allowed-be-compassionate/chronic-pain-overdose-crisis-and-unintended-harms-us

35.

Kilby

A. E.

(2015). Opioids of the masses: Welfare tradeoffs in the regulation of narcotic pain medications. http://economics.mit.edu/files/11150

36.

Komro

K. A.

O’Mara

R. J.

Wagenaar

A. C.

(2013). Public health law research: Theory and methods. In Wagenaar

A. C.

Burris

S. C.

(Eds.). Incorporated. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2273231

37.

Michaud

Kapteyn

Smith

van Soest

(2011). Temporary and permanent unit non-response in follow-up interviews of the Health and Retirement Study. Longitudinal and Life Course Studies: International Journal, 2(2), Article 114. https://doi.org/10.14301/llcs.v2i2.114

38.

National Academy of Sciences. (2017). Pain management and the opioid epidemic: Balancing societal and individual benefits and risks of prescription opioid use. The National Academies Press.

39.

Nicholas

L. H.

Maclean

J. C.

(2019). The effect of medical Marijuana laws on the health and labor supply of older adults: Evidence from the Health and Retirement Study. Journal of Policy Analysis and Management, 38(2), 455–480. https://doi.org/10.1002/pam.22122

40.

Peachman

R. R.

(2023). Will the new CDC opioid prescribing guidelines help correct the course in pain care? Journal of the American Medical Association, 329(2), 111–113. https://doi.org/10.1001/jama.2022.22284

41.

Picco

Lam

Haines

Nielsen

(2021). How prescription drug monitoring programs influence clinical decision-making: A mixed methods systematic review and meta-analysis. Drug and Alcohol Dependence, 228, Article 109090. https://doi.org/10.1016/j.drugalcdep.2021.109090

42.

Prescription Drug Monitoring Program Training and Technical Assistance Center. (2024). Mandatory PDMP use. https://www.pdmpassist.org/Content/Documents/pdf/Mandatory_Enrollment_Conditions.pdf

43.

Puac-Polanco

Chihuri

Fink

D. S.

Cerdá

Keyes

K. M.

(2020). Prescription drug monitoring programs and prescription opioid-related outcomes in the United States. Epidemiologic Reviews, 42, 134–153. https://doi.org/10.1093/epirev/mxaa002

44.

RAND-USC Schaeffer Opioid Policy Tools and Information Center. (2021a). OPTIC-vetted Marijuana policy data. https://www.rand.org/health-care/centers/optic/resources/datasets.html

45.

RAND-USC Schaeffer Opioid Policy Tools and Information Center. (2021b). OPTIC-Vetted PDMP Policy Data. Retrieved 10/20/21 from https://www.rand.org/health-care/centers/optic/resources/datasets.html

46.

Sehgal

Colson

Smith

H. S.

(2013). Chronic pain treatment with opioid analgesics: Benefits versus harms of long-term therapy. Expert Review of Neurotherapeutics, 13(11), 1201–1220. https://doi.org/10.1586/14737175.2013.846517

47.

Sherman

K. J.

Walker

R. L.

Saunders

Shortreed

S. M.

Parchman

Hansen

R. N.

Thakral

Ludman

E. J.

Dublin

Von Korff

(2018). Doctor-patient trust among chronic pain patients on chronic opioid therapy after opioid risk reduction initiatives: A survey. Journal of the American Board of Family Medicine, 31(4), 578–587. https://doi.org/10.3122/jabfm.2018.04.180021

48.

Sonnega

Faul

J. D.

Ofstedal

M. B.

Langa

K. M.

Phillips

J. W.

Weir

D. R.

(2014). Cohort profile: The Health and Retirement Study (HRS). International Journal of Epidemiology, 43(2), 576–585. https://doi.org/10.1093/ije/dyu067

49.

Substance Abuse and Mental Health Services Administration. (2024). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health (HHS publication no. PEP24-07-021, NSDUH Series H-59). https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report

50.

Szalavitz

(2022, March 22, 2022). What the opioid crisis took from people in pain. The New York Times. https://www.nytimes.com/2022/03/07/opinion/opioid-crisis-pain-victims.html

51.

Tay

Makeham

Laba

T. L.

Baysari

(2023). Prescription drug monitoring programs evaluation: A systematic review of reviews. Drug Alcohol Depend, 247, Article 109887. https://doi.org/10.1016/j.drugalcdep.2023.109887

52.

Tompkins

D. A.

Hobelmann

J. G.

Compton

(2017). Providing chronic pain management in the “Fifth Vital Sign” era: Historical and treatment perspectives on a modern-day medical dilemma. Drug and Alcohol Dependence, 173, S11–S21. https://doi.org/10.1016/j.drugalcdep.2016.12.002

53.

Upshur

C. C.

Bacigalupe

Luckmann

(2010). “They don’t want anything to do with you”: Patient views of primary care management of chronic pain. Pain Medicine, 11(12), 1791–1798. https://doi.org/10.1111/j.1526-4637.2010.00960.x

54.

Wetzel

von Esenwein

Yarbrough

C. R.

Hockenberry

J. M.

(2021). Association of prescription drug monitoring program laws with Bedridden and missed work days. Health Services Research, 56, 1215–1221.

55.

White

A. P.

Arnold

P. M.

Norvell

D. C.

Ecker

Fehlings

M. G.

(2011). Pharmacologic management of chronic low back pain: Synthesis of the evidence. Spine, 36, S131–S143. https://doi.org/10.1097/BRS.0b013e31822f178f

56.

Zimmer

Zajacova

(2020). Persistent, consistent, and extensive: The trend of increasing pain prevalence in older Americans. The Journals of Gerontology: Series B, 75(2), 436–447. https://doi.org/10.1093/geronb/gbx162

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

Do Must-Access Prescription Drug Monitoring Programs (PDMPs) Affect Pain and Impairment Outcomes in Older Adults?

Abstract

Keywords

Get full access to this article

References

Supplementary Material